# A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

> **NCT03104699** · PHASE1,PHASE2 · COMPLETED · sponsor: **Agenus Inc.** · enrollment: 211 (actual)

## Conditions studied

- Advanced Cancer
- Cervical Cancer

## Interventions

- **DRUG:** AGEN2034

## Key facts

- **NCT ID:** NCT03104699
- **Lead sponsor:** Agenus Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-11
- **Primary completion:** 2022-06-15
- **Final completion:** 2022-06-15
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03104699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03104699, "A Study of AGEN2034 in Advanced Tumors and Cervical Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03104699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*